Search for: "Sanofi-Aventis Deutschland GMBH" Results 1 - 20 of 28
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
29 Dec 2021, 4:16 pm by Lawrence B. Ebert
The outcome For the foregoing reasons, we affirm the four final written decisions that determined unpatentability based on Steenfeldt-Jensen: IPR2018-01670, IPR2018-01676, IPR2018-01678, and IPR2019-00979. [read post]
9 Jun 2008, 4:50 am
Sanofi-Aventis Deutschland GMBH et al. 2:08-cv-00258; filed June 5, 2008 in the Eastern District of Virginia Declaratory judgment of non-infringement and invalidity of U.S. [read post]
15 Jul 2008, 4:57 am
The patent was opposed by several companies involved in commercializing RNA interference (RNAi), including Sanofi-Aventis Deutschland GmbH, Sirna Therapeutics, Nucleonics, Inc., Quark Biotech, and Silence Therapeutics AG. [read post]
22 Apr 2014, 7:41 am
United Parcel Serv., Inc., 665 F.3d 68, 73 (3d Cir. 2012).Sanofi-Aventis Deutschland GMBH at *12.Jury InstructionsYou may make an adverse inference in this case against Glenmark. [read post]
5 Feb 2018, 9:59 pm by Patent Docs
Sanofi Aventis Deutschland GmbH PTAB Petition: IPR2017-01526; filed June 5, 2017. [read post]
24 May 2009, 10:58 pm
The opposing party, Sanofi-Aventis Deutschland GmbH, was represented by McDonnell Boehnen Hulbert & Berghoff LLP, of Chicago. [read post]
24 Apr 2014, 9:59 pm by Patent Docs
By Michael Greenfield -- On April 21, 2014, a Federal Circuit panel reiterated its interpretation and application to the chemical arts of the KSR obviousness standard. [read post]
21 Apr 2014, 2:03 pm by Dennis Crouch
According to the case, Sanofi-Aventis Deutschland GmbH is the owner of the patent at issue and Aventis Pharma S.A. is the exclusive licensee of that patent. [read post]
27 Sep 2020, 6:36 pm by Dennis Crouch
., No. 19-1452; Sanofi-Aventis Deutschland GmbH v. [read post]
5 Oct 2020, 10:25 am by Dennis Crouch
., No. 19-1452; Sanofi-Aventis Deutschland GmbH v. [read post]
22 Jul 2013, 3:51 am
It granted a licence to Sanofi-Aventis Deutschland GmbH to distribute it in Greece, under an authorisation to place it on the market granted by the competent Greek authorities in 1999. [read post]
19 Jun 2011, 9:00 pm by Laurent
Le recours aurait donc dû être formé au nom de Sanofi-Aventis Deutschland GmbH. [read post]
12 Oct 2011, 3:46 am by Marie Louise
No (FDA Law Blog) US: Patent battle over modified meganucleases heats up: Cellectis v Precision Biosciences (Holman’s Biotech IP Blog) (Patent Docs) US: Landmark NORD report on orphan drugs authored by HP&M Director shows FDA flexibility in approval (FDA Law Blog)   Products Embeda (Morphine sulfate, Naltrexone hydrochloride) – US: Pfizer, Alpharma, King Pharma. file patent infringement suit against Watson following Para IV certification (Patent Docs) Exelon (Rivastigmine)… [read post]
19 Jun 2011, 3:01 pm by Oliver G. Randl
The legal fact here was that the person aggrieved (i.e., adversely affected – see A 107) by the decision was Nutrinova (the food ingredients business of Celanese Ventures GmbH, to which company the relevant business assets had been transferred in July 2002). [read post]